Evidence-based cardiovascular magnetic resonance cost-effectiveness calculator for the detection of significant coronary artery disease
dc.contributor.author | Pandya, Ankur | |
dc.contributor.author | Yu, Yuan-Jui | |
dc.contributor.author | Ge, Yin | |
dc.contributor.author | Nagel, Eike | |
dc.contributor.author | Kwong, Raymond Y. | |
dc.contributor.author | Bakar, Rafidah A. | |
dc.contributor.author | Grizzard, John D. | |
dc.contributor.author | Merkler, Alexander E. | |
dc.contributor.author | Ntusi, Ntobeko | |
dc.contributor.author | Petersen, Steffen E. | |
dc.contributor.author | Rashedi, Nina | |
dc.contributor.author | Schwitter, Juerg | |
dc.contributor.author | Selvanayagam, Joseph B. | |
dc.contributor.author | White, James A. | |
dc.contributor.author | Carr, James | |
dc.contributor.author | Raman, Subha V. | |
dc.contributor.author | Simonetti, Orlando P. | |
dc.contributor.author | Bucciarelli-Ducci, Chiara | |
dc.contributor.author | Sierra-Galan, Lilia M. | |
dc.contributor.author | Ferrari, Victor A. | |
dc.contributor.author | Bhatia, Mona | |
dc.contributor.author | Kelle, Sebastian | |
dc.date.accessioned | 2022-01-09T01:03:32Z | |
dc.date.available | 2022-01-09T01:03:32Z | |
dc.date.issued | 2022-01-06 | |
dc.date.updated | 2022-01-09T01:03:32Z | |
dc.description.abstract | Abstract Background Although prior reports have evaluated the clinical and cost impacts of cardiovascular magnetic resonance (CMR) for low-to-intermediate-risk patients with suspected significant coronary artery disease (CAD), the cost-effectiveness of CMR compared to relevant comparators remains poorly understood. We aimed to summarize the cost-effectiveness literature on CMR for CAD and create a cost-effectiveness calculator, useable worldwide, to approximate the cost-per-quality-adjusted-life-year (QALY) of CMR and relevant comparators with context-specific patient-level and system-level inputs. Methods We searched the Tufts Cost-Effectiveness Analysis Registry and PubMed for cost-per-QALY or cost-per-life-year-saved studies of CMR to detect significant CAD. We also developed a linear regression meta-model (CMR Cost-Effectiveness Calculator) based on a larger CMR cost-effectiveness simulation model that can approximate CMR lifetime discount cost, QALY, and cost effectiveness compared to relevant comparators [such as single-photon emission computed tomography (SPECT), coronary computed tomography angiography (CCTA)] or invasive coronary angiography. Results CMR was cost-effective for evaluation of significant CAD (either health-improving and cost saving or having a cost-per-QALY or cost-per-life-year result lower than the cost-effectiveness threshold) versus its relevant comparator in 10 out of 15 studies, with 3 studies reporting uncertain cost effectiveness, and 2 studies showing CCTA was optimal. Our cost-effectiveness calculator showed that CCTA was not cost-effective in the US compared to CMR when the most recent publications on imaging performance were included in the model. Conclusions Based on current world-wide evidence in the literature, CMR usually represents a cost-effective option compared to relevant comparators to assess for significant CAD. | |
dc.identifier.citation | Journal of Cardiovascular Magnetic Resonance. 2022 Jan 06;24(1):1 | |
dc.identifier.doi | https://doi.org/10.1186/s12968-021-00833-1 | |
dc.identifier.uri | http://hdl.handle.net/1880/114265 | |
dc.identifier.uri | https://doi.org/10.11575/PRISM/45921 | |
dc.language.rfc3066 | en | |
dc.rights.holder | The Author(s) | |
dc.title | Evidence-based cardiovascular magnetic resonance cost-effectiveness calculator for the detection of significant coronary artery disease | |
dc.type | Journal Article |